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ABSTRACT  
Background: When estimating health state utility values (HSUV) for multiple health conditions, the 
alternative models used to combine these data can produce very different values.  Results generated 
using a baseline of perfect health are not comparable with those generated using a baseline adjusted for 
not having the health condition taking into account age and gender.  Despite this, there is no guidance 
on the preferred techniques that should be used and very little research describing the effect on cost per 
QALY results.   
 
Methods:  Using a cardiovascular disease (CVD) model and cost per QALY thresholds, we assess the 
consequence of using different baseline health state utility profiles (perfect health, individuals with no 
history of CVD, general population) in conjunction with three models (minimum, additive, 
multiplicative) frequently used to estimate proxy scores for multiple health conditions. 
 
Results: Assuming a baseline of perfect health ignores the natural decline in quality of life associated 
with co-morbidities, over-estimating the benefits of treatment to such an extent it could potentially 
influence a threshold policy decision.  The minimum model biases results in favour of younger aged 
cohorts while the additive and multiplicative technique produced similar results.   
 
Although further research in additional health conditions is required to support our findings, this pilot 
study highlights the urgent need for analysts to conform to an agreed reference case and provides initial 
recommendations for better practice.  We demonstrate that in CVD, if data are not available from 
individuals without the health condition, HSUVs from the general population provide a reasonable 
approximation. 
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INTRODUCTION 
 
A number of agencies, including the National Institute for Health and Clinical Excellence (NICE), 
require economic evidence to be presented in the form of cost-effectiveness analyses whereby health 
benefits are quantified by quality adjusted life years (QALYs).[1]  QALYs are calculated by summing 
the time spent in a health state weighted by the health state utility value (HSUV) associated with the 
health state thus incorporating both length of survival and HSUVs into a single metric.  Classification 
systems can produce a wide range of values for the same health state and the economic results 
generated using different systems are not always comparable.[1]  Consequently, for submissions in the 
UK, the Institute advocate a preference for EQ-5D data with HSUVs obtained using UK population 
weights when available.[1]   
 
However, this is not sufficient to ensure consistency across appraisals, as there is no guidance on 
appropriate baseline HSUVs.[1]  If a baseline utility of perfect health (i.e. EQ-5D equals 1) is used to 
represent the absence of a health condition, the incremental QALYs gained by an intervention are 
inflated[2] and the results obtained using a baseline of perfect health are not comparable with those 
obtained when the baseline is adjusted for not having a particular health condition.[3]  There is 
currently no consensus on baseline HSUVs used in economic evaluations. 
 
In addition, there is currently no directive on the method that should be used to combine HSUVs for 
multiple health conditions.  Analysts are increasingly exploring the benefits of interventions in 
individuals with several co-morbid conditions.  For example, HMG-CoA reductase inhibitors (statins) 
reduce both cardiovascular (CV) risk and rheumatoid arthritis (RA) disease activity and an economic 
model exploring the benefits of statins in this population would include health states for patients with a 
history of both RA and cardiovascular disease.[4]  Due to strict exclusion criteria preventing patients 
with co-morbidities entering clinical trials, it is unlikely that HSUVs will be available from patients 
with both health conditions.   
 
When HSUVs for the multiple health states are not available, proxy scores are estimated by combining 
data collected from patients with the individual health conditions.  Three methods are frequently used: 
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a) additive, b) multiplicative and c) minimum models.  The additive and multiplicative models assume 
a constant absolute or proportional effect respectively while the minimum model applies a disutility 
that can vary depending on the baseline utility modelled.  Research exploring the appropriateness of the 
techniques used to combine utility values is inconclusive.  The additive and multiplicative models have 
been shown to produce similar results for individuals with both diabetes and thyroiditis;[5] the 
multiplicative model produced accurate utilities for several other co-morbid conditions;[6] and the 
minimum model was advocated as the preferred methodology in two other studies.[7-8] 
 
While literature describing minimum requirements for probabilistic analyses is growing,[9] research 
exploring the basic principles involved in using HSUVs in economic models, and the implications for 
results generated from the models when using different techniques is scarce.  The limited research 
undertaken in this area has explored the appropriateness of different baseline utilities and proxy 
HSUVs for multiple health conditions in isolation and there is currently no consensus on the preferred 
methodologies when the two adjustments are undertaken together. 
 
We describe the results of a pilot study in which we explore the effect of using different baseline utility 
values and different techniques to estimate proxy HSUVs for multiple health conditions in 
combination.  We use an existing economic model and data from the Health Survey for England to 
investigate the potential effect on policy decision making using cost per QALY thresholds.  The 
primary objective of the study is to instigate additional research in this area to provide a foundation for 
better practice in economic evaluations used to inform health care decision makers in the UK and 
elsewhere. 
 
METHODS 
The following section provides a brief description of the economic model and a synopsis of the data 
used. 
 
Cardiovascular model 
An existing peer-reviewed Markov model[10] was modified slightly so the health states (Figure 1) 
matched the definitions of three cardiovascular conditions available from the Health Survey for 
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England which are angina (A), heart attack (HA) and stroke (Str).[10-11]  An annual cycle is used for 
transitions between health states.  Individuals enter the model in the event free health state (EF) and can 
move to a primary health state: angina (A), non-fatal heart attack (HA), or non-fatal stroke (Str), or 
remain in the EF health state.  Individuals in the primary and post-event health states can move to a 
subsequent health state: subsequent angina (SA), subsequent non-fatal HA (SHA), subsequent non-fatal 
stroke (SStr); or remain in the primary or post-event health state.  In each cycle all individuals are at 
risk of death through other causes (DoC), or fatal CVD (fCVD).  Health state costs are taken from a 
recent HTA evaluation of lipid treatments in the UK.[10] 
 
INSERT FIGURE 1:  Health states in cardiovascular model  
 
Health Survey for England 
The Health Survey for England (HSE) is conducted annually using random samples of the population 
living in private households in England.  The 2003 and 2006 surveys included questions about history 
of CVD and a random sample of participants (aged 16 to 98 years) were asked to complete the EQ-5D 
questionnaire (N=26,679).[11-12]  These data were used to estimate preference-based HSUVs using 
the weights obtained (based on time trade off valuations) from the UK general public.[13] 
 
 
INSERT TABLE 1: EQ-5D scores sub-grouped by health condition and time since event 
 
 
We assumed that the data from individuals who reported a history of just one CV condition are 
representative of the HSUVs of individuals who have a first ever primary CV event; and that data from 
individuals who reported a history of more than one CV condition are representative of the HSUVs of 
individuals who have a subsequent event (Table 1).  For example, the mean HSUV during the first 12 
months after experiencing a primary (secondary) heart attack is 0.721 (0.431) and the corresponding 
mean HSUV for time periods after this is 0.742 (0.685).   
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The relationship between HSUVs, age, sex and history of CVD was explored using ordinary least 
square regressions.  Model 1 (EQ-5D = 0.9508566 + 0.0212126*male - 0.0002587*age - 
0.0000332*age2, Figure 1) can be used to estimate the mean HSUVs for individuals in the general 
population and Model 2 (EQ-5D = 0.9454933 + 0.0256466*male - 0.0002213*age - 0.0000294*age2, 
Figure 2) can be used to estimate the HSUVs for individuals with no history of CVD.[14] 
 
INSERT Figure 2: Baseline utility for the event free health state: Relationship between HSUVs, 
age, sex and history of CVD 
 
ANALYSES 
The following section describes a worked example demonstrating the difference in incremental QALYs 
gained from avoiding a single event when using different baseline HSUV profiles, followed by results 
generated from the economic model demonstrating the potential effect on a policy decision using a cost 
per QALY threshold when using the different baseline HSUV profiles.  We then provide a worked 
example using the three alternative models to estimate proxy scores for multiple health conditions, 
looking at the difference in incremental QALYs associated with avoiding a single event, followed by 
results generated from the economic model when combining the different baseline profiles and the 
techniques used to combine the utility data.   
 
 
Baseline HSUV profiles 
In a CV model, individuals who are at high risk of a CV event and have no prior history of CVD 
typically enter the model in an “event free” health state.  The HSUV profile associated with this health 
state is then used as the baseline to estimate the health benefits accrued through avoiding CV events.  
Ideally, the health profile for the event free health state would be derived from long term registry data 
and would represent the HSUVs for individuals who are at high risk of a primary CV event but who 
have no existing history of CVD.  In the absence of these data, analysts assume the baseline HSUV 
profile is either a) equal to perfect health (i.e. EQ-5D = 1 irrespective of age or gender), b) equal to the 
profile of HSUVs from the general population adjusted for age and gender (i.e. all individuals 
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irrespective of history of CVD), or c) equal to the profile of HSUVs from individuals with no history of 
CVD.   
 
In the following example (Box 1), we illustrate the difference in QALYs accrued from avoiding a 
single event using the three alternative baseline HSUV profiles for the event free health state.  The 
HSUV profile when assuming a baseline of perfect health (UPHEF) is constant at EQ-5D = 1.   The 
HSUV profile when assuming a baseline from the individuals with no history of CVD (UNCVEF) is 
calculated using Model 2 and the HSUV profile when assuming a baseline from the general population 
(UGPEF) is calculated using Model 1 (Figure 1).  The mean EQ-5D score for individuals who reported 
experiencing angina within the previous 12 months (UA) is 0.6148 and the mean age for this subgroup 
is 68.8 years (Table 1).  We assume the event occurs at the age of 50 years and examine the cumulative 
and incremental QALYs accrued over a 50 year time horizon.  For the examples using the age-adjusted 
baseline profiles, the data for the individual health conditions are combined multiplicatively (see Box 2 
for more details on this technique).   
 
The cumulative QALYs for the event free health state are calculated by summing the life years 
weighted by the HSUV profile across the 50 year period (Cumulative QALYPHEF =50*1, Cumulative 
QALYNCVEF = å
££ 99age50
2  Model = 39.27, Cumulative QALYGPEF = å
££ 99age50
1  Model = 30.74.  The cumulative 
QALYs for angina are calculated by summing the life years weighted by the baseline profile multiplied 
by the multiplier associated with angina (Cumulative QALYPHA =50*1*0.6148 =30.74, Cumulative 
QALYNCVA = å
££ 99age50
2  Model *0.753= 29.56, Cumulative QALYGPA= å
££ 99age50
1  Model *0.771=29.37.  The 
incremental QALYs associated with avoiding angina is calculated as the difference between the total 
cumulative QALYs for the event free health state minus the total incremental QALYs for angina 
(Cumulative QALYiEF - Cumulative QALYA).  The technique used to obtain the multipliers is 
described in the next worked example. 
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Box 1:   Comparing the incremental QALY gain from a single event when using different 
  baseline HSUV profiles 
Let UPHEF = 1 
UNCVEF = 0.9454933 + 0.0256466 * male - 0.0002213 * age - 0.0000294 * age2  
UGPEF = 0.9508566 + 0.0212126 * male - 0.0002587 * age - 0.0000332 * age2  
UA = 0.6148 (mean age = 68.8 years) 
Where  Uij = HSUV, and  i = baseline:  PH = perfect health 
     NCV = no history of CVD (regression Model 2)  
     GP = general population (regression Model 1) 
   j = health state:  EF = event free, A = angina 
multiplier for angina for UNCV: male = 0.753 (= 0.6148/0.8167) 
multiplier# for angina for UGP: male = 0.771 (= 0.6148/0.7973)  
 (# see example 2 for method used to obtain multipliers) 
Results when assuming a baseline HSUV profile of full health: 
 Cumulative QALYPHEF = 50,  
Cumulative QALYPHA = 30.74 
 Incremental QALYPH = QALYPHEF - QALYPHA = 19.26  
Results when using a baseline HSUV profile from individuals with no history of CVD: 
 Cumulative QALYNCVEF = 39.27  
 Cumulative QALYNCVA = 29.56  
 Incremental QALYNCV = QALYNCVEF - QALYNCVA = 9.71  
Results when assuming a baseline HSUV profile from the general population: 
 Cumulative QALYGPEF = 38.08  
 Cumulative QALYGPA = 29.37  
 Incremental QALYGP = QALYGPEF - QALYGPA = 8.71  
 
Comparing results when using different baseline HSUV profiles for the event free health state 
For a male, the cumulative QALYs (Box 1) associated with remaining in the event free health state 
range from 38.1 when using a baseline HSUV profile from the general population to 50 when using a 
baseline HSUV profile of perfect health; and the cumulative QALYs associated with angina range from 
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29.4 when using a baseline HSUV profile from the general population to 30.7 when using a baseline 
HSUV profile of perfect health.  The incremental QALY gain associated with avoiding angina range 
from 8.71 when using a baseline HSUV profile from the general population to 19.26 when using a 
baseline HSUV profile of perfect health.  The incremental QALYs obtained using the baseline HSUV 
profile from the general population are comparable to those obtained when using the baseline HSUV 
profile from individuals with no history of CVD (8.71 versus 9.71).   
 
Looking at the QALY gain associated with avoiding a single heart attack or a stroke (Table 2), the 
values obtained when assuming a baseline HSUV profile of perfect health are substantially higher than 
those obtained using the age adjusted data.  Again the QALY gain obtained using the baseline HSUV 
profile from the general population are comparable to those obtained using the baseline HSUV profile 
from individuals with no history of CVD (heart attack: 4.30 versus 5.18; stroke: 8.33 versus 9.30). 
 
 
INSERT TABLE 2:  Cumulative and incremental QALYS associated with a single event using 
different baseline HSUV profiles 
 
 
Cost per QALY results using different baseline HSUV profiles for the event free health state 
The three alternative baseline profiles were applied in the CVD model and used to assess the lifetime 
benefits associated with avoiding primary events for cohorts of differing ages (Table 3).  The results 
from the worked example show the benefits associated with avoiding a single event are considerably 
larger when using a baseline of perfect health compared to adjusting the baseline.  When examining the 
effect on the results generated from the model, the cost per QALY obtained using a baseline of perfect 
health (Figure 3) is substantially lower than the corresponding results obtained using the age-adjusted 
profiles, particularly for the older aged cohorts.  If a threshold of £20,000 per QALY is applied (Figure 
3), using a baseline of perfect health could potentially induce a different policy decision than the one 
based on results generated when using a baseline HSUV profile that is adjusted for not having the 
health condition.    
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INSERT Table 3:  Results generated from CVD model using the three alternative baseline 
profiles 
 
INSERT Figure 3: Comparing the results generated from the CVD model using the three 
alternative baseline profiles 
 
Estimating proxy HSUV for multiple health conditions 
In the following example (Box 2) we use data from individuals who have a history of angina and no 
other CV condition (UA) and data from individuals who have a history of a heart attack and no other 
CV condition (UHA) to estimate a HSUV for the multiple health state “angina and heart attack” (UA,HA).  
The additive, multiplicative and minimum models are used to estimate the HSUV profiles for the 
multiple health condition in conjunction with the two age-adjusted baseline HSUV profiles (no history 
of CVD and general population) using the disutility (δij), multiplier (φij) or minimum value (min) 
respectively.  We compare the QALYs obtained from avoiding a single event when using the HSUV 
(UAHA) from individuals who have a history of both angina and a heart attack with those obtained when 
using the estimated HSUV (UA,HA).   
 
A. Using the USUV obtained from individuals with a history of both angina and heart attack 
The mean HSUV for individuals with a history of both angina and heart attack (UAHA) is 0.6243, and 
the mean age for this sub-group is 68.2 years.  When using the baseline HSUV profile from the general 
population, the HSUV for a male at the age of 68.2 years (UGP) is 0.8000 (from Model 1).  For the 
additive model, the disutility (δGPAHA) is the absolute difference between the baseline utility at the age 
of 68.2 years and the HSUV associated with the health condition angina and heart attack (i.e. δGPAHA 
=UGP-UAHA = 0.8000 – 0.6243 = 0.1757).  When summing the QALYs accumulated for the health 
condition, as the additive model assigns a constant effect irrespective of age, a constant value of 0.1757 
is deducted from the age-adjusted baseline HSUV each year and the resulting values are summed to 
give the total cumulative QALYs (QALYGPAHA= å
££ 99age50
AHA-1  Model
GPd  =29.30).  The incremental QALYs 
are then calculated by deducting the total cumulative QALYS associated with the condition angina and 
heart attack (QALYGPAHA=29.30) from the baseline total cumulative QALYs for the event free health 
state (QALYGPEF=38.08). 
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For the multiplicative model, the multiplier (φGPAHA) is the value that will give the HSUV associated 
with the health condition angina and heart attack (UAHA) when multiplying the baseline utility at the 
age of 68.2 years (i.e. φGPAHA =UAHA/UGP =0.6243/0.8000 =0.7804).  When summing the QALYs 
accumulated for the health condition, the multiplicative model assigns a constant proportional effect 
which is dependent on the age-adjusted baseline HSUV.  The total cumulative QALYs are calculated 
by summing the QALYs obtained when multiplying the age-adjusted baseline HSUV with the 
corresponding multiplier (QALYGPAHA= )*1  (Model
99age50
GP
AHAjå
££
=29.72).  The incremental QALYs are 
then calculated by deducting the total cumulative QALYS associated with the condition angina and 
heart attack (QALYGPAHA=29.72) from the baseline total cumulative QALYs for the event free health 
state (QALYGPEF=38.08).  For the minimum model, the minimum HSUV for the multiple condition 
angina and heart attack, and the age-adjusted baseline is used.  Consequently, the detriment associated 
with the health condition angina plus heart attack is not constant.  The total cumulative QALYs is 
simply the sum of the minimum values each year (QALYGPAHA= )U1,  min(Model
99age50
AHAå
££
=31.21).  
The incremental QALYs are then calculated by deducting the total cumulative QALYS for the health 
state angina plus heart attack (QALYGPAHA=31.21) from the baseline total cumulative QALYs for the 
event free health state (QALYGPEF=38.08). 
 
 
B. Using the HSUV obtained from individuals with a history of either angina (with no other CV 
condition) or heart attack (with no other CV condition) 
The mean HSUV for individuals with a history of just angina (UA) is 0.6910 and the mean HSUV for 
individuals with a history of just heart attack (UHA) is 0.7391.  The mean ages for these sub-groups are 
68.4 and 66.6 years respectively.  When using the baseline HSUV profile from the general population, 
the corresponding HSUVs for a male at the age of 68.4 and 66.6 years are 0.7990 and 0.8076 (from 
Model 1).  For the additive model, the total disutility (δGPA,HA) is estimated to be the sum of the 
absolute difference between the baseline utility at the age of 68.4 and the HSUV associated with the 
health condition angina (i.e. δGPA =UGP-UA = 0.7990 – 0.6910 = 0.1080) plus the absolute difference 
between the baseline utility at the age of 68.4 and the HSUV associated with the health condition heart 
attack (i.e. δGPHA =UGP-UHA = 0.8076 – 0.7391 = 0.0685), giving a total estimated detriment of 0.1765.  
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When summing the QALYs accumulated for the health condition, a constant value of 0.1765 is 
deducted from the age-adjusted baseline HSUV each year and the resulting values are summed to give 
the total cumulative QALYs (QALYGPA,HA= )1  (Model
99age50
GP
AHAd-å
££
 =29.25).  The incremental QALYs 
are then calculated by deducting the total cumulative QALYS (QALYGPA,HA=29.25) from the baseline 
total cumulative QALYs for the event free health state (QALYGPEF=38.08). 
 
For the multiplicative model, the estimated multiplier for the health state angina and heart attack 
(φGPA,HA) is calculated by multiplying the multiplier for angina (φGPA) with the multiplier for heart 
attack (φGPA).  The single multipliers are calculated using the method described earlier i.e. the 
multiplier for angina is obtained using the HSUV for angina and the baseline HSUV for individuals at 
the age of 68.4 years (φGPA=0.6910/0.7790) and the multiplier for heart attack is obtained using the 
HSUV for heart attack and the baseline HSUV for individuals at the age of 66.6 years 
(φGPA=0.7391/0.8076).  When multiplied together, the estimated multiplier for the combined conditions 
angina and heart attack (φGPA,HA) is 0.7915.  The total cumulative QALYs are calculated by summing 
the QALYs obtained when multiplying the age-adjusted baseline HSUV with the corresponding 
multiplier (QALYGPA,HA= )*1  (Model ,
99age50
GP
HAAjå
££
=30.14).  The incremental QALYs are then calculated 
by deducting the total cumulative QALYS associated with the condition angina and heart attack 
(QALYGPA,HA=30.14) from the baseline total cumulative QALYs for the event free health state 
(QALYGPEF=38.08). 
 
For the minimum model, the minimum HSUV for the individual conditions angina and heart attack, 
and the age-adjusted baseline is used.  The total cumulative QALYs is simply the sum of the minimum 
values each year (QALYGPA,HA= )U,U1,  min(Model
99age50
HAAå
££
=34.14).  The incremental QALYs are 
then calculated by deducting the estimated total cumulative QALYS for the health state angina plus 
heart attack (QALYGPA,HA=34.14) from the baseline total cumulative QALYs for the event free health 
state (QALYGPEF=38.08). 
 
Comparing results when estimating proxy HSUVs for multiple health conditions 
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When using age-adjusted baseline utilities from the general population to represent the HSUV for the 
event free health state, and the HSUV for individuals with a history of both angina and heart attack, the 
incremental QALYs obtained using the additive and the multiplicative models are 8.79 and 8.37 
compared with 6.88 when using the minimum model.  The corresponding incremental QALYs obtained 
when estimating HSUVs for the combined health state are 8.85, 7.96 and 3.95 for the additive, 
multiplicative and minimum models respectively.  If it is assumed that the values obtained using the 
data from individuals with both health conditions are correct, then the additive and multiplicative 
models produce much smaller errors in the incremental values than the minimum model. 
 
Using age-adjusted baseline utilities from individuals with no history of CVD to represent the HSUV 
profile for the event free health state (calculations provided in Box 2), the additive and the 
multiplicative models again produce similar results with incremental QALYs of 10.72 and 9.60 
respectively compared with 9.75 and 9.35 when using the data from individuals with a history of both 
conditions.  The incremental QALY gain when using the minimum model is much smaller at 4.81 and 
8.05 when using the HSUV from the individual health conditions and the HSUV from individuals with 
both health conditions respectively.   Results for additional examples (n ≥ 20) are provided in Table 4. 
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Box 2:  Estimating a proxy HSUV for the multiple health state both angina and heart attack 
Let j = health state and: AHA = both angina and heart attack, A =angina, HA =heart attack, 
    A,HA = proxy angina plus heart attack 
 δij = disutility; φij = multiplier; min =minimum 
 UAHA @ mean age 68.2 =0.6243, UGP @ age 68.2 =0.8000, UNCV @ age 68.2 =0.8193 
 UA @ mean age 68.4 =0.6910, UGP @ age 68.4 =0.7990, UNCV @ age 68.4 =0.8185 
 UHA @ mean age 66.6 =0.7391, UGP @ age 66.6 =0.8076, UNCV @ age 66.6 =0.8260 
Using a baseline HSUV profile from individuals with no history of CVD, 
Additive: δNCVAHA =UNCV - UAHA=0.8193 - 0.6243 =0.1950 
  δNCVA,HA =δNCVA + δNCVHA =(UNCV - UA)+(UNCV - UHA) 
   =(0.8185 - 0.6910)+(0.8260 - 0.7391) =0.2143 
Multiplicative: φNCVAHA =UAHA/UNCV =0.6243/0.8193 =0.7622 
  φNCVA, HA =φNCVA * φNCVHA =(UA/UNCV)*(UHA/UNCV) 
   =(0.6910/0.8185)*(0.7391/0.8260) =0.7555 
Minimum: UNCVAHA =min(UNCV,UAHA) =min(UNCV,0.6243) 
  UNCVA,HA =min(UNCV,UA,UHA) =min(UNCV,0.6910,0.7391) 
Assuming the event occurs at the age of 50 years, 
Using the data from individuals with a history of both angina and heart attack: 
 Additive, incremental QALYsNCV =QALYNCVEF - QALYNCVAHA =39.27 -29.52 =9.75 
 Multiplicative, incremental QALYsNCV =QALYNCVEF - QALYNCVAHA =39.27 - 29.92 =9.35 
 Minimum, incremental QALYsNCV =QALYNCVEF - QALYNCVAHA =39.27 - 31.22 =8.05 
Using the proxy scores from individuals with a history of either angina or heart attack: 
 Additive, incremental QALYsNCV =QALYNCVEF - QALYNCVA,HA =39.27 - 28.55 =10.72 
 Multiplicative, incremental QALYsNCV =QALYNCVEF - QALYNCVA,HA =39.27 - 29.67 =9.60 
 Minimum, incremental QALYsNCV =QALYNCVEF - QALYNCVA,HA =39.27 - 34.46 =4.81 
Using a baseline HSUV profile from the general population, 
Additive: δGPAHA = UGP-UAHA=0.8000 - 0.6243 =0.1757 
  δGPA,HA =δGPA +δGPHA =(UGP - UA)+(UGP -UHA) 
   =(0.7990 - 0.6910)+(0.8076 - 0.7391) =0.1765 
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Multiplicative: φGPAHA =UAHA/UGP =0.6243/0.8000 =0.7804 
  φGPA,HA =φmA *φmHA =(UA/UGP)*(UHA/UGP) 
   =(0.6910/0.7790)*(0.7391/0.8076) =0.7915 
Minimum: UGPAHA =min(UGP,UAHA) =min(UGP,0.6243) 
  UGPA,HA =min(UGP,UA,UHA) =min(UGP,0.6910,0.7391) 
Assuming the event occurs at the age of 50 years, 
Using the data from individuals with a history of both angina and heart attack: 
 Additive, incremental QALYsGP =QALYGPEF - QALYGPAHA =38.08 -29.30 =8.79 
 Multiplicative, incremental QALYsGP =QALYGPEF - QALYGPAHA =38.08 - 29.72 =8.36 
 Minimum, incremental QALYsGP =QALYGPEF - QALYGPAHA =38.08 - 31.21 =6.87 
Using the proxy scores from individuals with a history of either angina or heart attack: 
 Additive, incremental QALYsGP =QALYGPEF - QALYGPA,HA =38.08 - 29.25 =8.83 
 Multiplicative, incremental QALYsGP =QALYGPEF - QALYGPA,HA =38.08 - 30.14 =7.94 
 Minimum, incremental QALYsGP =QALYGPEF - QALYGPA,HA =38.08 - 34.14 =3.94 
N.B. any anomalies in the results are due to rounding in the decimal places in the calculations shown 
above 
 
 
 
INSERT Table 4: Cumulative and incremental QALY gains from a single event using 
different techniques to estimate proxy scores for multiple health states 
 
 
Cost per QALY results generated when combining the alternative baseline HSUV profiles with the 
three different models available to combine HSUVs 
The three alternative techniques used to combine utility scores are applied in the CVD model and used 
to assess the lifetime benefits associated with avoiding primary events for cohorts of differing ages 
using a baseline from individuals with no history of CVD and a baseline from individuals from the 
general population (Table 5).  The results from the second worked example showed the benefits 
associated with avoiding a single event are considerably smaller when using the minimum model to 
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combine the utility values.  This has a larger effect on the results for older aged cohorts (Table 5) where 
the ratio of costs and QALYs are more sensitive to small differences in the number of incremental 
QALYs gained.  Figure 4 shows the cost per QALY results generated from the model using the 
different techniques to combine the utility data.  There is very little difference in the results for the 
additive and multiplicative models, with the baseline HSUVs having a larger effect than the technique 
used to combine the utility data. 
 
INSERT Table 5:  Results generated from the CVD model when combining different baseline 
utility scores and different methods to combine utility data 
 
INSERT Figure 4: Comparing results generated from the CVD model when combining 
different baseline utility scores and different methods to combine utility data 
 
 
DISCUSSION 
We have demonstrated that the difference in QALY benefits accrued from avoiding a single CV event 
when using a baseline of perfect health are not comparable with those accrued when using a baseline 
that is adjusted for not having CVD.  We have also demonstrated that in CVD, results generated using 
age-adjusted data from the general population are comparable to those obtained using a baseline from 
individuals with no history of CVD.  Applying the different approaches in an economic model, we also 
show that assuming a HSUV profile of perfect health as the baseline could potentially influence a 
policy decision based on a cost per QALY threshold. 
 
The HSE data show that both age and gender are independent predictors of HSUVs and these findings 
are observed in numerous other datasets.[13,16]  Given that the mean EQ-5D score is never equal to 
full health irrespective of age or gender, using a baseline of perfect health overestimates the benefits 
associated with avoiding an event and biases the results in favour of the older age cohorts as it ignores 
the natural decline in mean HSUVs due to age and co-morbidities.  Data obtained from individuals 
without the health condition under consideration is the ideal baseline profile and should be used where 
possible.  However, if these data are not available, we show that in CVD, the results generated using 
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age-adjusted baseline data from the general population are comparable with the results generated using 
age-adjusted baseline data from individuals with no history of CVD.   
 
We demonstrated that when combined with the age-adjusted utilities, the method used to estimate 
proxy scores for multiple health conditions can produce a large variation in the incremental QALY gain 
from avoiding a single event.  When applying the techniques in the economic model we demonstrate 
that the method used to estimate the proxy scores could affect a policy decision based on a cost per 
QALY threshold.  In particular, using the minimum model in combination with an age-adjusted 
baseline produces results that are not comparable to those generated using the additive or multiplicative 
models.   
 
The existing literature describing the effect on results when combining HSUVs using the different 
methods is sparse and inconclusive.  Both Dale and Fu suggest the minimum value should be used to 
approximate the HSUV for a multiple health condition.[7-8]  By taking the minimum mean utility score 
of the individual health conditions that contribute to a multiple health condition, the minimum model 
assumes a co-morbidity has no additional detrimental effect on the HSUV of individuals with an 
existing health condition.  This is counterintuitive and data from the HSE show that in CVD there is a 
statistically significant difference in the mean EQ-5D score for individuals with one condition 
compared with those with more than one CV condition (mean EQ-5D for individuals with a history of 
just angina = 0.691, mean EQ-5D for individuals with a history of angina and stroke = 0.596, p<0.01).  
In addition, when applying the minimum model in an economic model in conjunction with an age-
adjusted baseline, the method fails.  The HSUVs for individuals who experience a primary heart attack 
is 0.7213.  In the primary prevention analyses where all individuals commence in the event free health 
state the age-adjusted EQ-5D score for males with no history of CVD at the age of 89 years is 0.718.  
Consequently, when using the minimum model there is no benefit in avoiding a non fatal heart attack in 
males over the age of 89 years.  Similarly the post primary angina health state has a mean EQ-5D score 
of 0.775 thus there are no benefits for males aged over 78 as the corresponding baseline age-adjusted 
EQ-5D score for individuals with no history of CVD is 0.7748.  As the minimum model does not apply 
a constant detriment the technique introduces a bias against older aged cohorts and the results from our 
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threshold analyses demonstrate this can be quite substantial.  We therefore recommend that the 
minimum model is not used to combine utility scores. 
 
Our results show that the multiplicative and additive models produce similar results both for the 
individual events and when applying the techniques in the economic model.  Flanagan and colleagues 
found the multiplicative model was reasonably accurate in estimating both double and triple co-
morbidities after “purifying” the mean HUI3 scores to adjust for not having 26 chronic conditions.[6]   
Bond and Freedburg concluded that the additive and multiplicative models produced very similar 
results, when using a baseline of perfect health.[5]   However, the additive model applies a constant 
absolute detriment across all ages while the multiplicative model applies a constant proportional 
detriment.  In real terms, this means that the additive model provides a greater absolute reduction in 
HSUVs than the multiplicative model and the magnitude of the detriment is constant across all ages 
irrespective of the number of co-morbidities.  The findings from Dale and Fu, who advocate the 
minimum model for combining HSUVs outside of an economic model, support the hypothesis that the 
detriment associated with several co-morbidities may not equal the sum of the individual detriments.   
 
Saarni reported that the mean number of co-morbid chronic conditions increases from 1.1 for the age 
group 30-44 years to 4.0 for those aged 75 years and older.[16]  It is possible that as the number of co-
morbidities increase, the detriment associated with an additional condition is smaller than that observed 
in an individual with just two co-morbidities.  If this hypothesis is correct, then the detriment associated 
with additional conditions would not be constant across all ages due to the increasing prevalence of co-
morbidities.  In addition, health conditions can impact on the same health dimensions and it is 
reasonable to assume that an individual with two or more similar conditions will not necessarily have a 
reduction in HSUV that is equal to the sum of the reductions observed for each of the individual health 
conditions.   
 
Although we found the additive and multiplicative models produced similar cost per QALY results this 
finding may not generalise to other health conditions.  In health conditions with comparatively small 
gains in QALYs, for example when the intervention does not have an effect on mortality rates, the 
economic results are likely to be more sensitive to changes in the techniques used to combine HSUVs.  
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While additional research is required to support our hypothesis and findings, in the interim period, to 
facilitate comparison across results generated from models with multiple health states, we advocate the 
use of the multiplicative model. 
 
The health care literature and policy decision makers such as NICE place a great deal of emphasis on 
both the methods used to obtain weights used in preference-based instruments and the particular 
preference-based instrument used to collect the HSUVs which are used to populate health states within 
economic models.[1]  Evidence shows that the choice of instrument used to represent the HSUVs of a 
particular health condition can influence the results generated.[15]  However, there is a great deal more 
to populating an economic model than the choice of instrument used to obtain the HSUVs and a 
consistent approach would improve comparability of results. 
 
 
Conclusion 
Our results re-enforce earlier recommendations and until guidelines are in place, we would recommend 
that data from the general population are used as proxy baseline utility measures for individuals 
without the health condition under consideration if the actual data is not available.  While our findings 
demonstrate the additive and multiplicative models give similar results in CVD, additional research in 
other health conditions and datasets are required. 
 
The underlying principle behind using the same preference-based instrument for all economic 
evaluations is to enable comparison across different interventions and health conditions.  If this is to be 
realised, some consensus is needed on the most appropriate methods to populate the economic models.  
The methods used should be clearly described to inform policy decision makers who are comparing 
results generated from different evaluations.   
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Figure 1: Health states in CVD model 
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Figure 2: Baseline utility for the event free health state: Relationship between HSUVs, age, sex 
and history of CVD 
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Figure 3: Comparing the results generated from the CVD model using the three alternative 
baseline profiles 
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PH = baseline of perfect health; NCV = baseline from individuals with no history of CVD; GP = 
baseline from the general population 
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Figure 4: Comparing results generated from the CVD model when combining different 
baseline utility scores and different methods to combine utility data  
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NCV = baseline from individuals with no history of CVD; GP = baseline from the general population; 
Add = additive model; Mult = multiplicative model; Min = minimum model. 
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Table 1: EQ-5D scores sub-grouped by health condition and time since event  
Age EQ-5D  Health condition health 
state 
N 
mean mean  se 
Utility values used to populate health states in the economic model 
Event free EF 25,080 47.0 0.872 0.001 
Angina < 12 months, history of just angina A 271 68.8 0.615 0.019 
No event < 12 months, history of just angina pA 246 68.0 0.775 0.015 
Angina < 12 months, history of angina + other CV condition SA 245 67.9 0.541 0.022 
No event < 12 months, history of angina + other CV condition  pSA 184 69.4 0.715 0.022 
Heart attack < 12 months, history of just heart attack HA 31 65.4 0.721 0.045 
No event < 12 months, history of just heart attack pHA 206 65.1 0.742 0.020 
Heart attack < 12 months, history of heart attack + other CV condition SHA 36 66.7 0.431 0.066 
No event < 12 months, history of heart attack + other CV condition pSHA 184 69.2 0.685 0.024 
Stroke < 12 months, history of just stroke Str 76 67.9 0.626 0.038 
No event < 12 months, history of just stroke pStr 291 66.8 0.668 0.018 
Stroke < 12 months, history of stroke + other CV condition SStr 18 73.5 0.479 0.087 
No event < 12 months, history of stroke + other CV condition pSStr 77 70.4 0.641 0.037 
Data used to compare methods for estimating proxy scores for multiple health conditions 
Angina (t=ever), history of just angina  517 68.4 0.691 0.013 
Heart attack (t=ever), history of just heart attack  237 66.6 0.739 0.018 
Stroke (t=ever), history of just stroke  367 67.0 0.660 0.016 
Angina and heart attack (t=ever)  323 68.2 0.624 0.019 
Angina and stroke (t=ever)  63 70.3 0.596 0.043 
Heart attack and stroke (t=ever)  32 69.7 0.538 0.065 
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Angina < 12 months and heart attack < 12 months   23 63.1 0.400 0.073 
Angina < 12 months and heart attack > 12 months  154 68.4 0.585 0.030 
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Table 2:   Cumulative and incremental QALYs associated with a single event using  
 different baseline utility data 
 Multiplicative Model 
 Cumulative QALY Incremental QALY 
 M F M F 
Baseline: perfect health 
Event free 50.00 50.00   
Angina 30.74 30.74 19.26 19.26 
Heart Attack 36.07 36.07 13.94 13.94 
Stroke 31.31 31.31 18.69 18.69 
Baseline: from general population 
Event free 38.08 37.02   
Angina 29.37 29.33 8.71 7.69 
Heart Attack 33.78 33.72 4.30 3.30 
Stroke 29.75 29.71 8.33 7.31 
Baseline: from individuals with no history of CVD 
Event free 39.27 37.99   
Angina 29.56 28.52 9.71 8.47 
Heart Attack 34.09 34.02 5.18 3.96 
Stroke 29.97 29.92 9.30 8.06 
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Table 3:  Results generated from CVD model using the three alternative baseline profiles 
(combining utility scores multiplicatively) 
  Baseline utility 
Treatment A 
QALYs 
Treatment B 
QALYs 
Incremental 
QALYs Cost per QALY 
Age 50 years 
Costs £(,000) £4,216 £5,610 £1,394   
 Perfect Health 16,795 16,895 100 £13,887 
 General Population 14,129 14,178 49 £28,324 
 No history of CVD 14,363 14,417 54 £25,914 
Age 60 years 
Costs £(,000) £3,660 £4,773 £1,113  
QALYs Perfect Health 13,582 13,648 67 £16,711 
 General Population 10,919 10,952 33 £33,957 
 No history of CVD 11,197 11,229 32 £34,777 
Age 70 years 
Costs £(,000) £2,609 £3,424 £815  
QALYs Perfect Health 9,966 10,002 36 £22,849 
 General Population 7,643 7,656 13 £62,195 
 No history of CVD 7,866 7,880 14 £56,487 
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Table 4: Cumulative and incremental QALY gains from a single event using different techniques to estimate proxy scores for multiple health states 
 Cumulative QALY Incremental QALY 
 Observeda  Proxyb Baseline -Observed Baseline- Proxy 
Error in Incremental 
QALY 
  GP NCVD GP NCVD GP NCVD GP NCVD GP NCVD 
 Baseline  
event free 38.1 39.3                 
 Angina plus Heart Attack: EQ-5D just angina = 0.691; EQ-5D just heart attack = 0.739; EQ-5D angina plus heart attack = 0.624   
additive 27.4 29.5 25.4 24.7 10.7 9.8 12.7 14.6 2.0 4.9 
multiplicative 27.9 28.1 26.8 26.4 10.2 11.2 11.3 12.9 1.1 1.7 
minimum 29.3 29.3 30.8 30.8 8.8 10.0 7.3 8.5 -1.5 -1.5 
 Angina plus Stroke: EQ-5D just angina =0.691; EQ-5D just stroke =0.660, EQ-5D angina plus stroke = 0.596 
additive 28.4 28.5 25.4 24.7 9.7 10.7 12.7 14.6 3.0 3.9 
multiplicative 28.7 28.9 27.0 26.5 9.4 10.4 11.1 12.7 1.8 2.3 
minimum 29.8 29.8 32.9 33.0 8.3 9.5 5.2 6.3 -3.1 -3.2 
Heart Attack plus Stroke: EQ-5D just heart attack = 0.739, EQ-5D just stroke = 0.660; EQ-5D heart attack plus stroke = 0.538 
additive 25.3 25.5 27.4 26.7 12.8 13.8 10.7 12.6 -2.0 -1.2 
multiplicative 25.8 26.0 28.6 28.1 12.2 13.3 9.5 11.1 -2.7 -2.1 
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minimum 26.9 26.9 32.9 33.0 11.2 12.4 5.2 6.3 -6.0 -6.1 
Angina < 12 months, Heart Attack < 12 months:  
EQ-5D angina < 12 months = 0.615; EQ-5D heart attack < 12 months = 0.721; EQ-5D angina < 12 months plus heart attack < 12 months = 0.400 
additive 16.9 17.3 24.4 23.7 21.2 22.0 13.7 15.6 -7.5 -6.4 
multiplicative 18.5 18.7 26.1 25.7 19.6 20.6 12.0 13.6 -7.6 -7.0 
minimum 20.0 20.0 30.8 30.8 18.1 19.3 7.3 8.5 -10.8 -10.8 
Angina < 12 months, Heart Attack > 12 months: 
EQ-5D angina < 12 months = 0.615; EQ-5D heart attack > 12 months = 0.742; EQ-5D angina < 12 months plus heart attack > 12 months = 0.585 
additive 27.4 27.6 25.4 24.7 10.7 11.7 12.7 14.6 2.0 2.9 
multiplicative 27.9 28.1 26.8 26.4 10.2 11.2 11.3 12.9 1.1 1.7 
minimum 29.3 29.3 30.8 30.8 8.8 10.0 7.3 8.5 -1.5 -1.5 
a using utility data from individuals with a history of both conditions; b using data from individuals with a history of a single condition to estimate the HSUV for the multiple 
health condition; GP = general population; NCVD = No history of CVD 
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Table 5: Results generated from the CVD model when combining different baseline utility 
scores and different methods to combine utility data 
General population No history of CVD  
additive multiplicative minimum additive multiplicative minimum 
Age 55 years 
Treatment A, total QALY 12,530 12,535 12,565 12,790 12,794 12,827 
Treatment B, total QALY 12,573 12,577 12,605 12,837 12,841 12,870 
Incremental QALY 43 43 40 47 47 43 
Cost per QALY £29,109 £29,394 £31,742 £26,664 £26,927 £29,088 
Age 65 years 
Treatment A, total QALY 9,257 9,262 9,298 9,510 9,515 9,553 
Treatment B, total QALY 9,282 9,286 9,318 9,537 9,542 9,576 
Incremental QALY 25 24 20 27 27 23 
Cost per QALY £38,680 £39,553 £47,253 £35,235 £36,021 £42,767 
Age 75 years 
Treatment A, total QALY 6,038 6,042 6,067 6,251 6,256 6,284 
Treatment B, total QALY 6,049 6,053 6,075 6,264 6,268 6,293 
Incremental QALY 11 11 8 13 12 9 
Cost per QALY £58,521 £61,078 £82,287 £52,676 £54,892 £74,144 
 
 
